Top

Hormones

Published in:

31-07-2023 | Mild Neurocognitive Disorder | Original Article

Uric acid index is a risk for mild cognitive impairment in type 2 diabetes

Authors: Xue-Wei Tong, Yi-Tong Zhang, Xin Li, Zi-Wei Yu, Sheng-Dan Pu, Yu-Xin Xu, Yong-Yan Shan, Xin-Yuan Gao

Published in: Hormones | Issue 3/2023

Abstract

Background

A new uric acid (UA) index has recently been proposed, while serum uric acid (SUA), fasting triglyceride, and fasting blood glucose levels in the index are shown to affect cognitive function. This study aims to investigate the clinical value of the UA index for assessing mild cognitive impairment (MCI) in type 2 diabetes (T2D) patients.

Methods

This was an observational cross-sectional study with 616 participants. A generalized additive model was used to determine a linear or curvilinear relationship between cognitive performance and the UA index. Logistic regression and random forest models were both developed. A receiver operating characteristic curve (ROC) was delineated and the area under the curve (AUC) was calculated.

Results

MCI was diagnosed in 313 participants (50.81%). Compared with the T2D-normal cognitive function group, MCI subjects had higher UA indexes, lower cognitive scores, and lower education levels (p < 0.001). Generalized additive models showed the UA index and the Montreal Cognitive Assessment (MoCA) score to be decreased linearly (p < 0.001). The UA index AUC was 0.751 (95% CI = 0.713–0.789, p < 0.001). The optimal cut-off point for the identification of MCI based on the UA index was 11.26 (sensitivity: 62.3%, specificity: 75.9%). Results for females in the cohort yielded an AUC change of + 2.5%, the less-educated population (AUC change of + 4.7%), and the hypertensive population (AUC change of + 1.1%). The AUCs were 0.791 (95% CI = 0.720–0.863) for the random forest model and 0.804 (95% CI = 0.770–0.837) for the logistic regression model, and no statistical significance was found (p = 0.758).

Conclusion

This study showed that the increased UA index was independently associated with MCI in patients with T2D, especially among female, less-educated, and hypertensive patients. It could be a potential indicator of MCI in T2D patients.

Available only for authorised users

2022 Alzheimer’s disease facts and figures. Alzheimers Dement 18(4):700–789. https://doi.org/10.1002/alz.12638

GBD 2019 Dementia Forecasting Collaborators (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7(2):e105–e125. https://doi.org/10.1016/s2468-2667(21)00249-8

Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A (2020) The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol 18(2):104–109. https://doi.org/10.2174/1570161117666190405165911CrossRefPubMed

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko E, JMagliano D J, (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https://doi.org/10.1016/j.diabres.2021.109119CrossRefPubMed

Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ (2020) Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 8(6):535–545. https://doi.org/10.1016/s2213-8587(20)30118-2CrossRefPubMed

Yuan X, Wang X (2017) Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. Rev. Neurosci. 28(7):715–723. https://doi.org/10.1515/revneuro-2017-0016CrossRefPubMed

Zheng T, Liu H, Qin L, Chen B, Zhang X, Hu X, Xiao LQin S, (2018) Oxidative stress-mediated influence of plasma DPP4 activity to BDNF ratio on mild cognitive impairment in elderly type 2 diabetic patients: results from the GDMD study in China. Metab Clin Exp 87:105–112. https://doi.org/10.1016/j.metabol.2018.03.014CrossRefPubMed

Shen X-N, Niu L-D, Wang Y-J, Cao X-P, Liu Q, Tan L, Zhang C-T (2019) Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry 90(5):590–598. https://doi.org/10.1136/jnnp-2018-319148CrossRefPubMed

Ekblad LL, Rinne JO, Puukka P, Laine H, Ahtiluoto S, Sulkava R, Viitanen M, Jula A (2017) Insulin resistance predicts cognitive decline: an 11-year follow-up of a nationally representative adult population sample. Diabetes Care 40(6):751–758. https://doi.org/10.2337/dc16-2001CrossRefPubMed

10.

Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ (2015) Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol 14(3):329–340. https://doi.org/10.1016/s1474-4422(14)70249-2CrossRefPubMed

11.

Veselý B, Koriťáková E, Bohnen NI, Viszlayová D, Királová S, Valkovič P, Kurča E, Rektor I (2019) The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson’s disease: preliminary observations. J Neural Transm (Vienna) 126(10):1303–1312. https://doi.org/10.1007/s00702-019-02043-7CrossRefPubMed

12.

Bowman GL, Shannon J, Frei B, Kaye J, AQuinn J F, (2010) Uric acid as a CNS antioxidant. J Alzheimers Dis 19(4):1331–1336. https://doi.org/10.3233/jad-2010-1330CrossRefPubMedPubMedCentral

13.

Chen C, Li X, Lv Y, Yin Z, Zhao F, Liu Y, Li C, Ji S, Zhou J, Wei Y, Cao X, Wang J, Gu H, Lu F, Liu Z, Shi X (2021) High blood uric acid is associated with reduced risks of mild cognitive impairment among older adults in china: a 9-year prospective cohort study. Front Aging Neurosci 13:747686. https://doi.org/10.3389/fnagi.2021.747686CrossRefPubMedPubMedCentral

14.

Scheepers L, Jacobsson LTH, Kern S, Johansson L, Dehlin M, Skoog I (2019) Urate and risk of Alzheimer’s disease and vascular dementia: a population-based study. Alzheimers Dement 15(6):754–763. https://doi.org/10.1016/j.jalz.2019.01.014CrossRefPubMed

15.

Euser SM, Hofman A, Westendorp RG, Breteler MM (2009) Serum uric acid and cognitive function and dementia. Brain 132(Pt 2):377–382. https://doi.org/10.1093/brain/awn316CrossRefPubMed

16.

Xue L, Liu Y, Xue H, Xue J, Sun K, Wu L, Hou P (2017) Low uric acid is a risk factor in mild cognitive impairment. Neuropsychiatr Dis Treat 13:2363–2367. https://doi.org/10.2147/ndt.S145812CrossRefPubMedPubMedCentral

17.

Maruhashi T, Hisatome I, Kihara Y, Higashi Y (2018) Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis 278:226–231. https://doi.org/10.1016/j.atherosclerosis.2018.10.007CrossRefPubMed

18.

Knapp LT, Klann E (2002) Potentiation of hippocampal synaptic transmission by superoxide requires the oxidative activation of protein kinase C. J Neurosci 22(3):674–683. https://doi.org/10.1523/jneurosci.22-03-00674.2002CrossRefPubMedPubMedCentral

19.

Schretlen DJ, Inscore AB, Jinnah HA, Rao V, Gordon B, Pearlson GD (2007) Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 21(1):136–140. https://doi.org/10.1037/0894-4105.21.1.136CrossRefPubMed

20.

Li J, Dong BR, Lin P, Zhang J, Liu GJ (2010) Association of cognitive function with serum uric acid level among Chinese nonagenarians and centenarians. Exp Gerontol 45(5):331–335. https://doi.org/10.1016/j.exger.2010.01.005CrossRefPubMed

21.

Vannorsdall TD, Kueider AM, Carlson MC, Schretlen DJ (2014) Higher baseline serum uric acid is associated with poorer cognition but not rates of cognitive decline in women. Exp Gerontol 60:136–139. https://doi.org/10.1016/j.exger.2014.10.013CrossRefPubMedPubMedCentral

22.

Kleber M, Delgado G, Grammer T, Silbernagel G, Huang J, Krämer B, Ritz E, März W (2015) Uric acid and cardiovascular events: a Mendelian randomization study. J the Am Soc Nephrol 26(11):2831–2838. https://doi.org/10.1681/asn.2014070660CrossRef

23.

Khalil M, Salwa M, Sultana S, Al Mamun M, Barman N, Haque M (2020) Role of serum uric acid in ischemic stroke: a case-control study in Bangladesh. Plos One 15(8):e0236747. https://doi.org/10.1371/journal.pone.0236747CrossRefPubMedPubMedCentral

24.

Yang XL, Kim Y, Kim TJ, Jung S, Kim CK, Lee SH (2016) Association of serum uric acid and cardioembolic stroke in patients with acute ischemic stroke. J Neurol Sci 370:57–62. https://doi.org/10.1016/j.jns.2016.09.019CrossRefPubMed

25.

Romero-Sevilla R, Casado-Naranjo I, Portilla-Cuenca JC, Duque-de San Juan B, Fuentes JM, Lopez-Espuela F (2018) Vascular risk factors and lesions of vascular nature in magnetic resonance as predictors of progression to dementia in patients with mild cognitive impairment. Curr Alzheimer Res 15(7):671–678. https://doi.org/10.2174/1567205015666180119100840CrossRefPubMed

26.

Perna L, Mons U, Schöttker B, Brenner H (2016) Association of cognitive function and serum uric acid: are cardiovascular diseases a mediator among women? Exp Gerontol 81:37–41. https://doi.org/10.1016/j.exger.2016.04.017CrossRefPubMed

27.

Huang R, Tian S, Han J, Lin H, Guo D, Wang J, An K, Wang S (2019) U-shaped association between serum uric acid levels and cognitive functions in patients with type 2 diabetes: a cross-sectional study. J Alzheimer’s Dis 69(1):135–144. https://doi.org/10.3233/jad-181126CrossRef

28.

Rojas-Humpire R, Jauregui-Rodriguez K, Albornoz S, Ruiz Mamani PG, Gutierrez-Ajalcrina R, Huancahuire-Vega S (2021) Association and diagnostic value of a novel uric acid index to cardiovascular risk. Pract Lab Med 26:e00247. https://doi.org/10.1016/j.plabm.2021.e00247CrossRefPubMedPubMedCentral

29.

Kinoshita T, Shimoda M, Sanada J, Fushimi Y, Hirata Y, Irie S, Tanabe A, Obata A, Kimura T, Hirukawa H, Kohara K, Tatsumi F, Kamei S, Nakanishi S, Mune T, Kaku K, Kaneto H (2016) Association of GA/HbA1c ratio and cognitive impairment in subjects with type 2 diabetes mellitus. J Diabetes Complicat 30(8):1452–1455. https://doi.org/10.1016/j.jdiacomp.2016.08.008CrossRef

30.

Huang X, Ng S, Chia N, Acharyya S, Setiawan F, Lu Z, Tan Y, Ng E, Wen M, Ng A, Tay K, Au W, Tan E, Tan L (2018) Higher serum triglyceride levels are associated with Parkinson’s disease mild cognitive impairment. Mov Disord 33(12):1970–1971. https://doi.org/10.1002/mds.27521CrossRefPubMed

31.

2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. (2020) Diabetes Care 43(Suppl 1):S14–s31. https://doi.org/10.2337/dc20-S002

32.

Yao L, Wang X, Zhong Y, Wang Y, Wu J, Geng J, Zhou Y, Chen J, Guan P, Xu Y, Chen L, Liu LHuY (2021) The triglyceride-glucose index is associated with diabetic retinopathy in Chinese patients with type 2 diabetes: a hospital-based, nested, case-control study. Diabetes Metab Syndr Obes 14:1547–1555. https://doi.org/10.2147/dmso.S294408CrossRefPubMedPubMedCentral

33.

Lv L, Zhou Y, Chen X, Gong L, Wu J, Luo W, Shen Y, Han S, Hu J, Wang Y, Li Q, Wang Z (2021) Relationship between the TyG index and diabetic kidney disease in patients with type-2 diabetes mellitus. Diabetes Metab Syndr Obes : Targets Ther 14:3299–3306. https://doi.org/10.2147/dmso.S318255CrossRef

34.

Flaxel C, Adelman R, Bailey S, Fawzi A, Lim J, Vemulakonda G, Ying G (2020) Diabetic retinopathy preferred practice pattern®. Ophthalmology 127(1):P66–P145. https://doi.org/10.1016/j.ophtha.2019.09.025CrossRefPubMed

35.

Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R, Malik R, Maser R, Sosenko J, Ziegler D (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28(4):956–962. https://doi.org/10.2337/diacare.28.4.956CrossRefPubMed

36.

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N, Gamst A, Holtzman D, Jagust W, Petersen R, Snyder P, Carrillo M, Thies B, Phelps C (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s and Dementia 7(3):270–279. https://doi.org/10.1016/j.jalz.2011.03.008CrossRefPubMed

37.

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.xCrossRefPubMed

38.

Álvarez-Lario B, Macarrón-Vicente J (2010) Uric acid and evolution. Rheumatology (Oxford) 49(11):2010–2015. https://doi.org/10.1093/rheumatology/keq204CrossRefPubMed

39.

Qiao M, Chen C, Liang Y, Luo Y, Wu W (2021) The influence of serum uric acid level on Alzheimer’s disease: a narrative review. Biomed Res Int 2021:5525710. https://doi.org/10.1155/2021/5525710CrossRefPubMedPubMedCentral

40.

Chen X, Wu G, Schwarzschild MA (2012) Urate in Parkinson’s disease: more than a biomarker? Curr Neurol Neurosci Rep 12(4):367–375. https://doi.org/10.1007/s11910-012-0282-7CrossRefPubMed

41.

Ya BL, Liu Q, Li HF, Cheng HJ, Yu T, Chen L, Wang Y, Yuan LL, Li WJ, Liu WY, Bai B (2018) Uric acid protects against focal cerebral ischemia/reperfusion-induced oxidative stress via activating Nrf2 and regulating neurotrophic factor expression. Oxid Med Cell Longev 2018:6069150. https://doi.org/10.1155/2018/6069150CrossRefPubMedPubMedCentral

42.

Desideri G, Gentile R, Antonosante A, Benedetti E, Grassi, D, Cristiano L, Manocchio A, Selli S, Ippoliti R, Ferri C, Borghi C, Giordano A, Cimini A (2017) Uric acid amplifies Aβ amyloid affects involved in the cognitive dysfunction/dementia: evidences from an experimental model in vitro. J Cell Physiol 232:1069–1078. https://doi.org/10.1002/jcp.25509

43.

Latourte A, Soumaré A, Bardin T, Perez-Ruiz F, Debette S, Richette P (2018) Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis 77(3):328–335. https://doi.org/10.1136/annrheumdis-2016-210767CrossRefPubMed

44.

Vannorsdall TD, Jinnah HA, Gordon B, Kraut M, Schretlen DJ (2008) Cerebral ischemia mediates the effect of serum uric acid on cognitive function. Stroke 39(12):3418–3420. https://doi.org/10.1161/strokeaha.108.521591CrossRefPubMedPubMedCentral

45.

Schretlen D, Inscore A, Vannorsdall T, Kraut M, Pearlson G, Gordon B, Jinnah H (2007) Serum uric acid and brain ischemia in normal elderly adults. Neurology 69(14):1418–1423. https://doi.org/10.1212/01.wnl.0000277468.10236.f1CrossRefPubMed

46.

Verhaaren B, Vernooij M, Dehghan A, Vrooman H, de Boer R, Hofman A, Witteman J, Niessen W, Breteler M, van der Lugt A, Ikram M (2013) The relation of uric acid to brain atrophy and cognition: the Rotterdam Scan Study. Neuroepidemiology 41(1):29–34. https://doi.org/10.1159/000346606CrossRefPubMed

47.

Shih C, Chen C, Wen C, Liu H, Kuo H (2012) Relationship between serum uric acid and cerebral white matter lesions in the elderly. Nutr Metab Cardiovasc Dis 22(2):154–159. https://doi.org/10.1016/j.numecd.2010.06.005CrossRefPubMed

48.

Mangge H, Zelzer S, Puerstner P, Schnedl W, Reeves G, Postolache T, Weghuber D (2013) Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Obesity (Silver Spring, Md.) 21(1):E71-77. https://doi.org/10.1002/oby.20061CrossRefPubMed

49.

Zhu Y, Hu Y, Huang T, Zhang Y, Li Z, Luo C, Luo Y, Yuan H, Hisatome I, Yamamoto T, Cheng J (2014) High uric acid directly inhibits insulin signalling and induces insulin resistance. Biochem Biophys Res Commun 447(4):707–714. https://doi.org/10.1016/j.bbrc.2014.04.080CrossRefPubMed

50.

Ford E, Li C, Cook S, Choi H (2007) Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115(19):2526–2532. https://doi.org/10.1161/circulationaha.106.657627CrossRefPubMed

51.

Ndrepepa G (2018) Uric acid and cardiovascular disease. Int J Clin Chem 484:150–163. https://doi.org/10.1016/j.cca.2018.05.046CrossRef

52.

Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Ko K, Jung G, Lee HN, Lee JY, Sohn CH, Lee YS, Shin SA, Kim YK, Lee DY (2020) Serum uric acid, Alzheimer-related brain changes, and cognitive impairment. Front Aging Neurosci 12:160. https://doi.org/10.3389/fnagi.2020.00160CrossRefPubMedPubMedCentral

53.

Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, Ciebiada M, Loba J (2015) C-reactive protein, advanced glycation end products, and their receptor in type 2 diabetic, elderly patients with mild cognitive impairment. Front Aging Neurosci 7:209. https://doi.org/10.3389/fnagi.2015.00209CrossRefPubMedPubMedCentral

54.

Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37(1):67–76. https://doi.org/10.1016/j.nbd.2009.09.008CrossRefPubMed

55.

Nägga K, Gustavsson AM, Stomrud E, Lindqvist D, van Westen D, Blennow K, Zetterberg H, Melander O, Hansson O (2018) Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later. Neurology 90(1):e73–e81. https://doi.org/10.1212/wnl.0000000000004749CrossRefPubMedPubMedCentral

56.

Lee YG, Park M, Jeong SH, Kang SW, Baik K, Jung JH, Lee PH, Sohn YH, Ye BS (2021) Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism. Neurobiol. Aging 106:223–231. https://doi.org/10.1016/j.neurobiolaging.2021.05.003CrossRefPubMed

57.

Carcaillon L, Brailly-Tabard S, Ancelin ML, Rouaud O, Dartigues JF, Guiochon-Mantel A, Scarabin PY (2014) High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology 82(6):504–511. https://doi.org/10.1212/wnl.0000000000000107CrossRefPubMed

58.

Kong J, Kang M, Kang H (2022) The relationship between late-life depression and cognitive function in older Korean adults: a moderation analysis of physical activity combined with lower-body muscle strength. Int J Environ Res Public Health 19(14):8769. https://doi.org/10.3390/ijerph19148769

59.

Eikelboom WS, Pan M, Ossenkoppele R, Coesmans M, Gatchel JR, Ismail Z, Lanctôt KL, Fischer CE, Mortby ME, van den Berg E, Papma JM (2022) Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis. Alzheimers Res Ther 14(1):48. https://doi.org/10.1186/s13195-022-00991-zCrossRefPubMedPubMedCentral

60.

Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctôt KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Ballard C, Khin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG (2013) Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement 9(5):602–608. https://doi.org/10.1016/j.jalz.2012.12.001CrossRefPubMedPubMedCentral

61.

Chen Y, Lv C, Li X, Zhang J, Chen K, Liu Z, Li H, Fan J, Qin T, Luo L, Zhang Z (2019) The positive impacts of early-life education on cognition, leisure activity, and brain structure in healthy aging. Aging (Albany NY) 11(14):4923–4942. https://doi.org/10.18632/aging.102088CrossRefPubMed

62.

Wang Q, Shen JJ, Sotero M, Li CA, Hou Z (2018) Income, occupation and education: are they related to smoking behaviors in China? Plos One 13(2):e0192571. https://doi.org/10.1371/journal.pone.0192571CrossRefPubMedPubMedCentral

63.

Barr PB, Salvatore JE, Maes H, Aliev F, Latvala A, Viken R, Rose RJ, Kaprio J, Dick DM (2016) Education and alcohol use: a study of gene-environment interaction in young adulthood. Soc Sci Med 162:158–167. https://doi.org/10.1016/j.socscimed.2016.06.031CrossRefPubMedPubMedCentral

64.

Atella V, Kopinska J (2014) Body weight, eating patterns, and physical activity: the role of education. Demography 51(4):1225–1249. https://doi.org/10.1007/s13524-014-0311-zCrossRefPubMed

65.

Choi AI, Weekley CC, Chen SC, Li S, Kurella Tamura M, Norris KC, Shlipak MG (2011) Association of educational attainment with chronic disease and mortality: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 58(2):228–234. https://doi.org/10.1053/j.ajkd.2011.02.388CrossRefPubMedPubMedCentral

66.

Tefera YA, Bishu KG, Gebregziabher M, Dawson AZ, Egede LE (2019) Source of education, source of care, access to glucometers, and independent correlates of diabetes knowledge in Ethiopian adults with diabetes. J Natl Med Assoc 111(2):218–230. https://doi.org/10.1016/j.jnma.2018.10.008CrossRefPubMed

67.

Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JT (2020) Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension 76(1):217–225. https://doi.org/10.1161/hypertensionaha.120.14993CrossRefPubMed

68.

Petrova M, Prokopenko S, Pronina E, Mozheyko E (2010) Diabetes type 2, hypertension and cognitive dysfunction in middle age women. J Neurol Sci 299(1–2):39–41. https://doi.org/10.1016/j.jns.2010.08.057CrossRefPubMed

69.

Borshchev YY, Uspensky YP, Galagudza MM (2019) Pathogenetic pathways of cognitive dysfunction and dementia in metabolic syndrome. Life Sci 237:116932. https://doi.org/10.1016/j.lfs.2019.116932CrossRefPubMed

Title: Uric acid index is a risk for mild cognitive impairment in type 2 diabetes
Authors: Xue-Wei Tong
Yi-Tong Zhang
Xin Li
Zi-Wei Yu
Sheng-Dan Pu
Yu-Xin Xu
Yong-Yan Shan
Xin-Yuan Gao
Publication date: 31-07-2023
Publisher: Springer International Publishing
Keywords: Mild Neurocognitive Disorder
Type 2 Diabetes
Diabetic Nephropathy
Published in: Hormones / Issue 3/2023
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI: https://doi.org/10.1007/s42000-023-00465-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Which method is more effective in predicting adult height in pubertal girls treated with gonadotropin-releasing hormone agonist?

The role of various influence sources on sexual behavior in adolescents with type 1 diabetes in comparison to healthy peers: a cross-sectional study from Greece

Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in a patient with systemic lupus erythematosus and antiphospholipid syndrome: case presentation and review of the literature

Hybrid closed-loop systems can help patients with extreme fear of hypoglycemia or hyperglycemia

Women with type 1 diabetes gain more weight during pregnancy compared to age-matched healthy women despite a healthier diet: a prospective case–control observational study

Associations between serum vitamin D status and the cardiometabolic profile of patients with obstructive sleep apnea

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials